Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

sNDA for Clonicel submitted to the FDA

Addrenex Pharmaceuticals and Sciele Pharma, Inc., a Shionogi company today announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD).

2 Oct 2009

Clinical study results demonstrate the efficacy of AFRESA inhalation powder

AFRESA (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, showed no significant changes in pulmonary function and sustained glycemic control in adult patients with type 2 diabetes over four years of continuous treatment, according to data presented today at the 45th Annual Meeting of the European Association for the Study of Diabetes.

2 Oct 2009

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

Halozyme Therapeutics, Inc. today announced additional Phase 2 results that demonstrated faster insulin absorption and increased peak insulin concentrations in type 1 diabetic patients after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with Humulin® R (regular human insulin), a mealtime insulin.

1 Oct 2009

Addrenex submits a sNDA to the FDA for Clonicel

Sciele Pharma, Inc., a Shionogi company, and Addrenex Pharmaceuticals today announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD).

1 Oct 2009

Diamyd Medical signs agreement with Inclinix to conduct global Phase III program

Diamyd Medical announces today that the company has signed an agreement with Inclinix Inc., North Carolina, for accelerated recruitment of children and adolescents recently diagnosed with type 1 diabetes in the US Phase III study of the diabetes vaccine Diamyd(R).

1 Oct 2009

Treating mothers for mild gestational diabetes reduces infant deaths and birth-related complications

Treating pregnant women for mild gestational diabetes resulted in fewer cesarean sections and other serious birthing problems associated with larger than average babies, according to a study conducted in part at the University of North Carolina at Chapel Hill.

1 Oct 2009

Sanofi-aventis announces study results comparing efficacy of Lantus to detemir

Sanofi-aventis announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine (rDNA) injection) compared to twice-daily insulin detemir. The study was presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.

30 Sep 2009

Genetic factors play an important role in the development of type 1 diabetes

Under the direction of Prof. Dr. Anette Ziegler, scientists of the Diabetes Research Group at Helmholtz Zentrum München and Technische Universität München investigated the formation of antibodies to a zinc transporter in children with elevated risk for type 1 diabetes. The study provided indications of an early onset of the disease when specific antibodies in the blood and specific variants of the associated zinc transporter are present in the genome.

30 Sep 2009

AFRESA Inhalation Powder and AFRESA Inhaler NDA under FDA review

AFRESA® (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin able to more closely replicate normal glucose suppression than currently available insulins, according to data presented at the 45th Annual Meeting of the European Association for the Study of Diabetes.

30 Sep 2009

Metabolic syndrome related to elevated levels of liver enzymes in obese teenagers

Researchers studying a large sample of adolescent American boys have found an association between metabolic syndrome, which is a complication of obesity, and elevated liver enzymes that mark potentially serious liver disease.

30 Sep 2009

Vitae receives 11Beta-HSD-1 program milestone payment from Boehringer Ingelheim

Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned an $8 million milestone payment from Boehringer Ingelheim for achievement of a performance milestone in their 11beta-hydroxysteroid dehydrogenase (HSD)-1 diabetes and metabolic disease strategic alliance.

29 Sep 2009

AAP receives grant to promote awareness on childhood obesity

The American Academy of Pediatrics (AAP) announces that it has been awarded a $250,000 grant from MetLife Foundation, to promote community and regional approaches to obesity prevention. Through the grant, AAP will launch two national grant programs, which are focused on encouraging both established pediatricians and pediatricians-in-training to develop collaborative methods to educate communities about the health effects of childhood obesity.

29 Sep 2009

Diabetics should monitor their blood sugar levels to improve metabolic status

Diabetes patients should always control their own blood sugar values if this leads to improvements in their treatment. This is the view advocated by Michael Nauck of the Bad Lauterberg Diabetes Center and his coauthors in the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2009; 106[37]: 587-94), who discuss sensible approaches to blood glucose self-monitoring.

29 Sep 2009

Sciele Pharma files NDA for glycopyrrolate oral solution

Sciele Pharma, Inc., a Shionogi company, today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for glycopyrrolate oral solution to treat chronic, moderate-to-severe drooling in pediatric patients. This condition often results from cerebral palsy as well as from other neurological disorders.

29 Sep 2009

NHGRI and NIMH fund $45 million to establish Centers of Excellence in Genomic Science

The National Human Genome Research Institute (NHGRI) and National Institute of Mental Health (NIMH), both part of the National Institutes of Health, today announced grants expected to total approximately $45 million to establish new Centers of Excellence in Genomic Science at the Medical College of Wisconsin and University of North Carolina, Chapel Hill as well as to continue support of existing centers at Johns Hopkins University and the University of Southern California.

29 Sep 2009

Januvia in combination with metformin or taken alone lowers blood sugar

A post-hoc analysis, presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), of data pooled from studies of 104 weeks in duration showed ‘Januvia’ (sitagliptin), when taken alone or in combination with metformin, provided significant blood sugar lowering over two years.

29 Sep 2009

Blood vessels in the retina may help predict risk of heart attack or stroke

For centuries eyes have been seen as windows to the soul. But medical researchers now believe the eyes may also offer vital clues to your risk of heart disease and stroke.

28 Sep 2009

Halozyme Therapeutics announces Phase 1 clinical study to assess three insulin analogs

Halozyme Therapeutics, Inc. today announced the commencement of a Phase 1 clinical study that will assess the effects of three approved prandial (mealtime) insulin analogs administered with its proprietary rHuPH20 (PH20) hyaluronidase enzyme compared to each of the analogs alone. This randomized, three-way cross-over design, euglycemic clamp study will compare the postprandial pharmacokinetics (PK) and glucodynamics (GD) of the insulin analogs.

28 Sep 2009

Diabetic hypoglycemia remains a critical concern in young patients

A recent Lancet article predicted a doubling of new cases of type 1 diabetes in European children aged under 5, and a 70% rise in cases in children under 15 years - an incidence rate exceeding all previous predictions. Studies in the USA and other countries also suggest similar trends.

28 Sep 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009